CD8A and melanoma: Clinical studies showed that combining T-VEC (Talimogene laherparepvec), an oncolytic virus, with pembrolizumab achieved higher response rates, up to 62%, in melanoma, compared to 33% with immune checkpoint inhibitors alone, accompanied by increased intra-tumoral CD8+ T cells and reduced immunosuppressive populations [133].